BACKGROUND: The transient receptor potential (TRP) superfamily of ion channels are a large and diverse group that have received increased attention in recent years. The sub-family of thermo-TRPs which are regulated by temperature, among other physical and chemical stimuli, are of particular interest for the development of potential pain therapeutics. OBJECTIVE/ METHODS: We review the advances in the field in recent years, focusing on a rationale for pain therapy and potential challenges associated with these targets. RESULTS/ CONCLUSIONS: Vanilloid-type TRP 1 (TRPV1) is the most well studied and advanced member of the family, with selective agonists and antagonists already in clinical use or development, respectively. Among other thermo-TRPs (including TRPV2 - 4, Ankyrin type TRP 1 (TRPA1) and melastatin type TRP 8 (TRPM8)), TRPA1 and TRPM8 are emerging as promising novel pain targets.
BACKGROUND: The transient receptor potential (TRP) superfamily of ion channels are a large and diverse group that have received increased attention in recent years. The sub-family of thermo-TRPs which are regulated by temperature, among other physical and chemical stimuli, are of particular interest for the development of potential pain therapeutics. OBJECTIVE/ METHODS: We review the advances in the field in recent years, focusing on a rationale for pain therapy and potential challenges associated with these targets. RESULTS/ CONCLUSIONS: Vanilloid-type TRP 1 (TRPV1) is the most well studied and advanced member of the family, with selective agonists and antagonists already in clinical use or development, respectively. Among other thermo-TRPs (including TRPV2 - 4, Ankyrin type TRP 1 (TRPA1) and melastatin type TRP 8 (TRPM8)), TRPA1 and TRPM8 are emerging as promising novel pain targets.
Authors: Lesley M Arnold; Jinbo Fan; I Jon Russell; Muhammad B Yunus; Muhammad Asim Khan; Irving Kushner; Jane M Olson; Sudha K Iyengar Journal: Arthritis Rheum Date: 2013-04
Authors: Olivera Grubisha; Adrian J Mogg; Jessica L Sorge; Laura-Jayne Ball; Helen Sanger; Cara L A Ruble; Elizabeth A Folly; Daniel Ursu; Lisa M Broad Journal: Br J Pharmacol Date: 2014-05 Impact factor: 8.739
Authors: Asia Fernández-Carvajal; Gregorio Fernández-Ballester; Isabel Devesa; José Manuel González-Ros; Antonio Ferrer-Montiel Journal: Pharmaceuticals (Basel) Date: 2011-12-27